What does the evidence say about Glucosamine Joint Health Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Glucosamine Joint Health Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - Meta-analyses were performed using random-effects models, and the GRADE methodology was applied to assess the certainty of the evidence. [Calzada-Gonzales N (2026); evidence level 1] - In patients with TMJ OA, compared with placebo, glucosamine may not result in a clinically important reduction in pain at ≤3 months (MD -1.58 mm; 95% CI -5.98 to 2.83; low certainty) and probably does not provide a clinically important reduction at 6 months despite statistical significance (MD -7.02 mm; 95% CI -11.95 to -2.09; moderate certainty). [Calzada-Gonzales N (2026); evidence level 1] - Glucosamine improved quality of life at 12 months (MD -4.14; 95% CI -6.41 to -1.87; high certainty). [Calzada-Gonzales N (2026); evidence level 1] - Background Glucosamine has been proposed as a therapeutic option for temporomandibular disorders (TMD), particularly temporomandibular joint osteoarthritis (TMJ OA), but its effectiveness and safety remain uncertain. [Calzada-Gonzales N (2026); evidence level 1] - This umbrella review synthesized evidence from published systematic reviews and meta-analyses on the effectiveness and safety of glucosamine in knee OA. [Li Y (2026); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.